Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Hubber SA
Original Assignee
Laboratorios Hubber SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Hubber SAfiledCriticalLaboratorios Hubber SA
Priority to ES550071ApriorityCriticalpatent/ES8702384A1/en
Publication of ES550071A0publicationCriticalpatent/ES550071A0/en
Publication of ES8702384A1publicationCriticalpatent/ES8702384A1/en
N-Sulphamoyl 3-(22-guanidino- thiazol-4-yl)methylthio) propionamidine, for use in inhibition of gastric secretions, is made by reaction of 3-chloro priopionamidine with a small excess of (2-guanidino thiazol-4-yl)methyl mercaptan, in organic solvent e.g. dry ethanol, made alkaline, with dry hydroxide, initially at 0-10 deg.C and later at reflux temp. The solvent is removed by distn and the residue purified by chromatography.
PROCEDURE FOR OBTAINING N-2-5- (DIMETHYLAMINE) METHYL-2-FURANIL METHYL THIO-N-METHYL-2-NITRO-1,1-ETHENODIAMINE. (Machine-translation by Google Translate, not legally binding)
Procedure for the obtaining of N- (2- (((5- ((dimethylamino) methyl) -2-furanil) methyl) tio) ethyl) -n'-methyl-2-nitro-1,1-etenodyamine (Machine-translation by Google Translate, not legally binding)